A century of cholesterol and coronaries: from plaques to genes to statins

JL Goldstein, MS Brown - Cell, 2015 - cell.com
One-fourth of all deaths in industrialized countries result from coronary heart disease. A
century of research has revealed the essential causative agent: cholesterol-carrying low …

Chemically modified platforms for better RNA therapeutics

Y Shi, X Zhen, Y Zhang, Y Li, S Koo, Q Saiding… - Chemical …, 2024 - ACS Publications
RNA-based therapies have catalyzed a revolutionary transformation in the biomedical
landscape, offering unprecedented potential in disease prevention and treatment. However …

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events

MS Sabatine, RP Giugliano, SD Wiviott… - … England Journal of …, 2015 - Mass Medical Soc
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …

Long-read sequencing of 3,622 Icelanders provides insight into the role of structural variants in human diseases and other traits

D Beyter, H Ingimundardottir, A Oddsson… - Nature …, 2021 - nature.com
Long-read sequencing (LRS) promises to improve the characterization of structural variants
(SVs). We generated LRS data from 3,622 Icelanders and identified a median of 22,636 SVs …

The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association

SS Gidding, M Ann Champagne, SD de Ferranti… - Circulation, 2015 - Am Heart Assoc
2168 Circulation December 1, 2015 sufficient evidence for health benefit exists to implement
case finding via family history–based screening, cascade screening, or other strategies …

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the …

M Cuchel, E Bruckert, HN Ginsberg… - European heart …, 2014 - academic.oup.com
Abstract Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening
condition characterized by markedly elevated circulating levels of low-density lipoprotein …

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …

FJ Raal, EA Stein, R Dufour, T Turner, F Civeira… - The Lancet, 2015 - thelancet.com
Background Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …

Dyslipidemia in obesity: mechanisms and potential targets

B Klop, JWF Elte, M Castro Cabezas - Nutrients, 2013 - mdpi.com
Obesity has become a major worldwide health problem. In every single country in the world,
the incidence of obesity is rising continuously and therefore, the associated morbidity …

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

FJ Raal, N Honarpour, DJ Blom, GK Hovingh, F Xu… - The Lancet, 2015 - thelancet.com
Background Homozygous familial hypercholesterolaemia is a rare, serious disorder caused
by very low or absent plasma clearance of LDL, substantially raised LDL cholesterol, and …

Diagnosis and treatment of heterozygous familial hypercholesterolemia

MP McGowan, SH Hosseini Dehkordi… - Journal of the …, 2019 - Am Heart Assoc
Familial hypercholesterolemia (FH) is a common yet underdiagnosed autosomal dominant
disorder that affects% 1 in 220 individuals globally. 1 FH is characterized by lifelong …